{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T21:11:18Z","timestamp":1760735478372,"version":"build-2065373602"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.ejca.2020.10.022","type":"journal-article","created":{"date-parts":[[2020,12,3]],"date-time":"2020-12-03T14:04:56Z","timestamp":1607004296000},"page":"52-54","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Consideration regarding immune checkpoint inhibitor\u2013induced secondary adrenal insufficiency in patients lacking human leucocyte antigen-DR15"],"prefix":"10.1016","volume":"143","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4447-3064","authenticated-orcid":false,"given":"Akinori","family":"Kanzaki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taiichirou","family":"Otsuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tohru","family":"Arii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7930-2228","authenticated-orcid":false,"given":"Hidenori","family":"Koyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoru","family":"Katayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2020.10.022_bib1","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ejca.2020.02.049","article-title":"Human leucocyte antigen DR15, a possible predictive marker for immune checkpoint inhibitor-induced secondary adrenal insufficiency","volume":"130","author":"Yano","year":"2020","journal-title":"Eur J Canc"},{"key":"10.1016\/j.ejca.2020.10.022_bib2","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.biopha.2018.02.103","article-title":"The potential pathogenic role of IL-17\/Th17 cells in both type 1 and type 2 diabetes mellitus","volume":"101","author":"Abdel-Moneim","year":"2018","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.ejca.2020.10.022_bib3","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1507\/endocrj.EJ18-0396","article-title":"Upregulated tissue expression of T helper (Th) 17 pathogenic interleukin (IL)-23 and IL-1\u03b2 in Hashimoto's thyroiditis but not in Graves' disease","volume":"66","author":"Zake","year":"2019","journal-title":"Endocr J"},{"key":"10.1016\/j.ejca.2020.10.022_bib4","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1474-4422(03)00308-9","article-title":"Multiple sclerosis in the Japanese population","volume":"2","author":"Kira","year":"2003","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.ejca.2020.10.022_bib5","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1399-0039.2008.01172.x","article-title":"Association of the HLA-DPB1\u22170501 allele with anti-aquaporin-4 antibody positivity in Japanese patients with idiopathic central nervous system demyelinating disorders","volume":"73","author":"Matsushita 1","year":"2009","journal-title":"Tissue Antigens"},{"key":"10.1016\/j.ejca.2020.10.022_bib6","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s12885-018-3997-2","article-title":"Neuromyelitis optica spectrum disorder secondary to treatment withanti-PD-1 antibody nivolumab: the first report","volume":"18","author":"Narumi","year":"2018","journal-title":"BMC Canc"},{"issue":"21","key":"10.1016\/j.ejca.2020.10.022_bib7","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2020.10.022_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40842-019-0092-9","article-title":"Isolated ACTH deficiency during single-agent pembrolizumab for squamous cell lung carcinoma: a case report","volume":"6","author":"Tanaka","year":"2020","journal-title":"Clin Diabetes Endocrinol"},{"key":"10.1016\/j.ejca.2020.10.022_bib9","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/imj.13787","article-title":"Hypothalamic demyelination causing panhypopituitarism","volume":"48","author":"Dixon-Douglas","year":"2018","journal-title":"Intern Med J"},{"key":"10.1016\/j.ejca.2020.10.022_bib10","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.endonu.2010.11.004","article-title":"Partial adrenocorticotropin hormone deficiency associated with multiple sclerosis","volume":"58","author":"Mat\u00edas-Guiu","year":"2011","journal-title":"Endocrinol Nutr"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804920313058?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804920313058?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:29:28Z","timestamp":1760732968000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804920313058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":10,"alternative-id":["S0959804920313058"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2020.10.022","relation":{},"ISSN":["0959-8049"],"issn-type":[{"type":"print","value":"0959-8049"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Consideration regarding immune checkpoint inhibitor\u2013induced secondary adrenal insufficiency in patients lacking human leucocyte antigen-DR15","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2020.10.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2020.02.049","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}